Sandbox g12: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 54: | Line 54: | ||
::* [[Clarithromycin|Clarithromycin (Biaxin®, Prevpac®)]] | ::* [[Clarithromycin|Clarithromycin (Biaxin®, Prevpac®)]] | ||
::* [[Erythromycin|Erythromycin (A/T/S®, Akne-Mycin®, Emgel®, Ery-Tab®, Eryc®, Erycette®, Eryderm®, Erygel®)]] | ::* [[Erythromycin|Erythromycin (A/T/S®, Akne-Mycin®, Emgel®, Ery-Tab®, Eryc®, Erycette®, Eryderm®, Erygel®)]] | ||
::* [[Itraconazole]] | ::* [[Itraconazole|Itraconazole (Sporanox®, Onmel®)]] | ||
::* [[Ketoconazole]] | ::* [[Ketoconazole|Ketoconazole (Nizoral®, Sebizole®, Ketomed®, Keton®)]] | ||
::* [[Pentamidine|Pentamidine (Pentam®)]] | ::* [[Pentamidine|Pentamidine (Pentam®)]] | ||
::* [[Sparfloxacin|Sparfloxacin (Zagam®)]] | ::* [[Sparfloxacin|Sparfloxacin (Zagam®)]] | ||
:* '''Schedule IV (Minimal risk for TdP, case reports of TdP, mild IKr blockade, may have CYP interactions)''' | :* '''Schedule IV (Minimal risk for TdP, case reports of TdP, mild IKr blockade, may have CYP interactions)''' | ||
::* [[Fluconazole]] | ::* [[Fluconazole|Fluconazole (Diflucan®, Trican®)]] | ||
::* [[Gatifloxacin]] | ::* [[Gatifloxacin|Gatifloxacin (Tequin®)]] | ||
::* [[Gemifloxacin]] | ::* [[Gemifloxacin|Gemifloxacin (Factive®)]] | ||
::* [[ | ::* [[Levofloxacin|Levofloxacin (Levaquin®, Tavanic®)]] | ||
::* [[Moxifloxacin|Moxifloxacin (Avelox®, Avalox®, Avelon®)]] | |||
::* [[Moxifloxacin]] | ::* [[Telithromycin|Telithromycin (Ketek®)]] | ||
::* [[Telithromycin | |||
:* '''Schedule V (Questionable | ::* [[Voriconazole|Voriconazole (VFend®)]] | ||
::* [[Azithromycin ]] | |||
::* [[Ciprofloxacin ]] | :* '''Schedule V (Questionable or minimal risk for QT interval prolongation or TdP)''' | ||
::* [[Sulfamethoxazole- | ::* [[Azithromycin|Azithromycin (Zithromax®, Zmax®)]] | ||
::* [[Ciprofloxacin|Ciprofloxacin (Cipro®, Cipro-XR®, Neofloxin®)]] | |||
::* [[Trimethoprim-Sulfamethoxazole|Trimethoprim-Sulfamethoxazole (Septra®, Bactrim®, Sulfatrim®, Biseptol®, Co-trimoxazole®, Cotrim®, Septrin®, Trisul®)]] | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 21:55, 31 May 2015
- Risk categories for antimicrobial agents known to have an association with TdP[1]
- Drugs with known TdP risk
- Azithromycin (Zithromax®, Zmax®)
- Chloroquine (Aralen®)
- Ciprofloxacin (Cipro®, Cipro-XR®, Neofloxin®)
- Clarithromycin (Biaxin®, Prevpac®)
- Erythromycin (A/T/S®, Akne-Mycin®, Emgel®, Ery-Tab®, Eryc®, Erycette®, Eryderm®, Erygel®)
- Fluconazole (Diflucan®, Trican®)
- Halofantrine (Halfan®)
- Levofloxacin (Levaquin®, Tavanic®)
- Moxifloxacin (Avelox®, Avalox®, Avelon®)
- Pentamidine (Pentam®)
- Sparfloxacin (Zagam®)
- Drugs with possible TdP risk
- Atazanavir (Reyataz®)
- Bedaquiline (Sirturo®)
- Dihydroartemisinin-Piperaquine (Eurartesim®)
- Foscarnet (Foscavir®)
- Gatifloxacin (Tequin®)
- Gemifloxacin (Factive®)
- Norfloxacin (Noroxin®, Ambigram®)
- Ofloxacin (Floxin®)
- Rilpivirine (Edurant®, Complera®, Eviplera®)
- Roxithromycin (Rulide®, Xthrocin®, Roxl-150®, Roxo®, Surlid®, Rulide®, Biaxsig®, Roxar®, Roximycinv®, Roxomycin®, Rulid®, Tirabicin®, Coroxin®)
- Saquinavir (Invirase®(combo))
- Telavancin (Vibativ®)
- Telithromycin (Ketek®)
- Drugs with conditional TdP risk
- Amantadine (Symmetrel®, Symadine®)
- Hydroxychloroquine (Plaquenil®, Quineprox®)
- Itraconazole (Sporanox®, Onmel®)
- Ketoconazole (Nizoral®, Sebizole®, Ketomed®, Keton®)
- Metronidazole (Flagyl® and many others)
- Nelfinavir (Viracept®)
- Posaconazole (Noxafil®, Posamol®)
- Quinine sulfate (Qualaquin®)
- Ritonavir (Norvir®)
- Telaprevir (Incivek®, Incivo®)
- Voriconazole (VFend®)
- Drugs to be avoided by congenital Long QT
- Torsades de pointes risk stratification schedules for antimicrobial agents[2]
- Schedule I (Highest TdP risk, potent IKr blockers, TdP risk >1%)
- Not available
- Schedule II (Significant risk for TdP, particularly when coadministered with CYP inhibitors, relatively potent IKr blockade)
- Not available
- Schedule III (Risk for TdP is described, IKr blockade, particularly when coadministered with CYP inhibitors)
- Schedule IV (Minimal risk for TdP, case reports of TdP, mild IKr blockade, may have CYP interactions)
- Schedule V (Questionable or minimal risk for QT interval prolongation or TdP)